Anti-Human IL-6R (Sarilumab) – APC
Anti-Human IL-6R (Sarilumab) – APC
Product No.: LT1703
Product No.LT1703 Clone Hu137 Target IL-6 Product Type Biosimilar Recombinant Human Monoclonal Antibody Alternate Names Interleukin-6, CDF; HGF; HSF; BSF2; BSF-2; IFNB2; IFN-beta-2 Isotype Human IgG1κ Applications FA , FC , IHC |
Antibody DetailsProduct DetailsReactive Species Human Host Species Human Expression Host HEK-293 Cells FC Effector Activity Active Product Concentration 0.2 mg/ml Formulation This Allophycocyanin (APC) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative. Storage and Handling This Allophycocyanin (APC) conjugate is stable when stored at 2-8°C. Do not freeze. Regulatory Status Research Use Only (RUO). Non-Therapeutic. Country of Origin USA Shipping Next Day 2-8°C Excitation Laser Red Laser (650 nm) RRIDAB_2893928 Applications and Recommended Usage? Quality Tested by Leinco FC The suggested concentration for Alemtuzumab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application. Additional Applications Reported In Literature ? IHC (Paraffin) IHC (Frozen) Additional Reported Applications For Relevant Conjugates ? FA WB B N Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity This non-therapeutic antibody uses the same variable region sequence as the therapeutic antibody Sarilumab. Sarilumab binds to the transmembrane and soluble forms of the IL-6 receptor. This product is for research use only. Background IL-6 and its signaling pathway play a part in immune response regulation, inflammation, and hematopoiesis.2 Sarilumab is a research-grade recombinant human monoclonal IL-6 receptor antagonist. It specifically binds to both the transmembrane and soluble forms of the IL-6 receptor, thus inhibiting IL-6–mediated cis and trans-signaling in a dose-dependent manner.1 Therapeutic Sarilumab, also known by the trade name Kevzara, is currently used to treat Rheumatoid Arthritis1, however, as of March 2020, The Feinstein Institute of Northwell Health publicized a study on "a human antibody that may prevent the activity" of IL-6 for the treatment of COVID-19.3 Anti-Human IL-6 (Sarilumab) utilizes the same variable regions from the therapeutic antibody Sarilumab making it ideal for research projects. Antigen Distribution IL-6R is ubiquitously expressed. PubMed NCBI Gene Bank ID UniProt.org Research Area Biosimilars . Cell Biology . Immunology . Innate Immunity . Neuroscience . Other Molecules Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Research-grade Sarilumab biosimilars are commonly utilized as calibration standards and reference controls in pharmacokinetic (PK) bridging ELISA assays to accurately measure drug concentration in serum samples. In these methods, the biosimilar is selected as the analytical standard—meaning the calibrator used to generate a standard curve against which serum samples and quality control materials are quantified. Essential context and details:
Additional relevant information:
Flow Cytometry Protocols Using Sarilumab Biosimilar for IL-6 Target ValidationConjugated Sarilumab biosimilar antibodies (e.g., PE- or APC-labeled) can be used to validate expression or binding of the IL-6 receptor (IL-6R) on human cells via flow cytometry. Below is a summary of the standard protocols, based on available product details and recommended practices from manufacturers and relevant literature. Key Protocol StepsSample Preparation
Antibody Staining
Flow Cytometry Acquisition
Data Analysis
Practical Considerations
Example Protocol Outline
Summary Table of Key Parameters
ConclusionStandard flow cytometry protocols for validating IL-6R expression or binding using conjugated Sarilumab biosimilar require careful cell preparation, antibody titration, proper controls, and data analysis focused on MFI and percent positivity. These protocols are robust for both expression validation and functional binding assessments, but always verify with your antibody’s product sheet and adjust as needed for your experimental system. Biopharma companies employ a comprehensive suite of analytical assays to demonstrate that proposed biosimilars are highly similar to their reference products in both structure and function. This analytical characterization forms the foundation of the biosimilar development process and regulatory approval pathway. Structural Characterization AssaysThe structural assessment begins with primary structure analysis, which includes amino acid sequencing to confirm identical primary amino acid structure between the biosimilar and reference product. Companies utilize advanced analytical techniques including circular dichroism and nuclear magnetic resonance spectroscopies to analyze higher-order protein structure and folding patterns. Peptide mapping is employed to detect post-translational modifications and structural variants. This technique can reveal differences in glycosylation profiles, deamidation, oxidation, and other chemical modifications that may occur during manufacturing. Mass spectrometry-based approaches provide detailed molecular weight analysis and can identify product-related variants such as aggregates, precursors, fragments, or other modified forms. Glycan analysis represents a particularly critical component, as glycosylation patterns can significantly impact biological function. Companies conduct comprehensive profiling of N-linked and O-linked glycans to ensure similarity in these complex carbohydrate structures. Functional Characterization AssaysWhile structural similarity is necessary, it is not sufficient for biosimilar approval. Functional assays serve as the crucial link between structural data and clinical expectations. These assays answer the vital question of whether any minor structural differences observed during characterization translate into functionally significant differences. Binding assays constitute a major category of functional testing, including target binding studies to assess how effectively the biosimilar binds to its intended therapeutic target. For monoclonal antibodies, this includes Fc receptor binding assays that evaluate binding affinity to immune receptors like FcγRIIIa. These studies can demonstrate that even if slight glycosylation differences exist, they don't impact functionally relevant binding interactions. Bioassays and mechanism-of-action studies evaluate the biological activity and potency of the biosimilar compared to the reference product. These may include cell-based assays that measure biological responses, enzyme kinetics studies, and other functional readouts specific to the therapeutic mechanism. Quality and Purity AssessmentThe analytical similarity assessment must include rigorous comparison of purity and impurity profiles. This encompasses testing for process-related impurities, product-related variants, and degradation products. Companies conduct extensive characterization across multiple lots of both the proposed biosimilar and reference product to establish appropriate limits, ranges, or distributions for comparison. Potency testing ensures optimal biological activity, while immunogenicity assessment evaluates the potential for unwanted immune responses through various in vitro and in vivo approaches. Orthogonal Methods and Risk-Based ApproachModern biosimilar development employs multiple complementary or orthogonal analytical methods to comprehensively characterize product properties and sensitively assess potential differences. This multi-method approach provides robust evidence of similarity from different analytical perspectives. Companies utilize a risk-based approach to prioritize testing, ranking molecular properties by their potential impact on activity, pharmacokinetics, pharmacodynamics, safety, efficacy, or immunogenicity. Critical quality attributes (CQAs) that are most relevant to clinical outcomes receive particular focus based on the nature of the protein and its mechanism of action. Regarding the specific mention of "Leinco biosimilar" in your query, the search results provided do not contain any information about this particular biosimilar or its use in analytical studies. The analytical approaches described above represent the standard methodologies used across the biosimilar industry for demonstrating similarity to reference products, but without additional information, I cannot provide specific details about how Leinco biosimilars are utilized in these analytical workflows. References & Citations1. Kevzara (sarilumab) injection [prescribing information]. Tarrytown, NY: Regeneron Pharmaceuticals; Bridgewater, NJ: sanofi-aventis U.S.; May 2017. 2. Yoshida Y, Tanaka T. Interleukin 6 and rheumatoid arthritis. Biomed Res Int. 2014;2014:698313. 3. "Northwell Health Initiates Clinical Trials of 2 COVID-19 Drugs". 21 March 2020. Technical ProtocolsCertificate of Analysis |
Formats Available
Prod No. | Description |
---|---|
LT1700 | |
LT1703 | |
LT1704 | |
LT1702 | |
LT1701 | |
LT1711 | |
LT1706 | |
LT1705 | |
LT1707 |
